fluoroquinolonethyroid.com

As such, it is not a reliable “gateway screening” criterion in patients with negative ANA’s and obvious symptomatology representative of a variety of known neurological, neuromuscular, and rheumatological conditions. Based on current knowledge, FDA warnings, and published research about the CNS and PNS Fluoroquinolone-Induced Symptoms ... ................
................

In order to avoid copyright disputes, this page is only a partial summary.